2025-11-05T23:47:06-07:00 2025-06-30 990 2024-07-01 030485196 MYELIN REPAIR FOUNDATION INC MYEL 20111 Edinburgh Drive Saratoga CA 95070 Scott Johnson Chief Executive Officer 4087610201 2025-11-06 1 2024 2025-03-06 01:10:19Z Scott Johnson 20111 Edinburgh Drive Saratoga CA 95070 267774 0 X myelinrepair.org X 2002 CA Accelerating the development of new therapeutics to prevent or repair damage to myelin caused by Multiple Sclerosis. Myelin Repair Foundation is helping to identify biomarkers of myelin repair for use in myelin repair drug development and clinical trials 5 4 1 0 0 0 201187 167240 0 0 52232 37734 12652 62800 266071 267774 310296 208000 0 0 143278 146982 0 0 14358 50130 158012 503704 512994 -237633 -245220 1295871 877106 607261 433716 688610 443390 Accelerating the development of new therapeutics to prevent or repair damage to myelin caused by Multiple Sclerosis. The MRF is helping to identify biomarkers of myelin repair for use in myelin repair drug development and clinical trials 0 0 485640 208000 268148 We only have one area of program services and that is scientific research to benefit Multiple Sclerosis (MS) patients. Currently our research is focused on experiments to identify biomarkers to indicate repair of myelin damaged by MS. Over the last year, we focused our research on extracellular vesicles(EVs) isolated from blood. We currently have 8 investigations underway spread across Europe and North America. We have encouraging preliminary data showing that we can clearly distinguish MS patient EV's from healthy controls and may be able to identify sub-types of MS. 0 0 0 485640 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 5 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 X 5 4 0 0 0 0 0 0 0 1 1 1 0 1 1 1 1 1 1 1 0 0 CA X Louise Savoie 4088885542 2198 Hillstone Dr San Jose CA 95138 Scott Johnson CEO 20 X 120000 0 0 Andy Cates Director 1 0 X 0 0 0 Bobby Mehta Director 1 0 X 0 0 0 Jim Gidwitz Director 1 0 X 0 0 0 Eric Hsu Director 1 0 X 0 0 0 120000 0 0 1 0 0 0 Susan Goelz 6900 SE 35th Avenue Portland OR 97202 Analysis of Scientific Research Agreement Results 127157 1 0 0 0 0 0 167240 0 167240 0 0 0 0 0 37734 37734 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 62800 62800 0 0 62800 267774 100534 0 0 X 100000 100000 0 0 108000 108000 120000 103200 6000 10800 17368 14936 868 1564 9614 8268 481 865 5020 5020 137657 137657 12545 10789 627 1129 2790 2790 512994 485640 12996 14358 84313 15535 1054139 818937 143000 35000 14419 7634 1295871 877106 607261 433716 607261 433716 X 688610 443390 0 0 688610 443390 1295871 877106 -245220 0 0 0 0 0 X 0 0 0 X 478580 262804 527737 201187 167240 1637548 478580 262804 527737 201187 167240 1637548 839203 798345 699 914 31061 52232 84906 51048 21709 0 12652 62800 148209 1870663 0.42677 0.49498 X Schedule A, Part II, Line 10 Unused Scientific Research Agreement Funds. On occasion, SRAs use less than the amount granted. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 Europe (including Iceland and Greenland) 0 0 Program Services The overall objective of this project is to develop an analytical pipeline to assess the cargo of EVs found in the serum and secreted by neurons, astrocytes and oligodendrocytes. This pipeline will then be used to identify a blood-derived signature of MS. Extracellular vesicles offer a promising avenue for the discovery of biomarkers to help tackle multiple sclerosis progression. By analyzing the cargo of EVs, we hope to obtain valuable insights on neuroinflammation, neurodegeneration, and treatment response. As the field advances and standardization efforts progress, EV-based biomarkers may revolutionize disease monitoring, personalized treatment approaches, and the development of novel therapeutics ultimately leading to improved outcomes for patients with multiple sclerosis. 108000 0 0 108000 Europe (including Iceland and Greenland) Scientific research 108000 cash progress payments 0 contractual amount 0 1 0 0 0 0 0 0 Schedule F, Part I, Line 2 Grants outside the United States are treated the same as grants within the United States with regular required reports and conversations with recipients 1 Yale University 25 Science Park 150 Munson St New Haven CT 06520 060646973 100000 0 contractual amount There are two scientific research agreements with Yale for $50,000 each. The first is to validate the exosomal small RNA biomarker for MS progression in an additional validation cohort, consisting of 40 progressive and stable MS patients and then confirm the astrocyte origin of progression-associated RNAs by verifying their expression or downregulation in reactive astrocytes in autopsied brain tissue from progressive MS patients. Lastly, to test whether GLAST+ exosomes from progressive but not stable MS patients or healthy controls induce proinflammatory pathways in human iPSC-derived microglial cells that are also active in microglial populations in the brain of progressive MS patients. The second SRA aims to Develop a robust protocol to isolate OL-derived exosomes and quantify their lipid and protein content and determine the small RNA, lipid and proteomic signatures in oligodendrocyte-exosomes correlated to remyelination using samples from the RENEW optic neuritis treatment trial. 1 0 Schedule I, Part I, Line 2 The recipients are subject to the terms and conditions of the sponsored research agreement between them and MRF. The researcher's work is reviewed by the MRF Scientific Director, the Executive Committee, and the MRF president. Form 990, Part VI, Section A, Line 9 Andy Cates-429N Main Street,suite 100, Memphis, TN 38103; Jim Gidwitz -440 S LaSalle, suite 3100, Chicago IL 60605; Bobby Mehta-159 E Walton Street Chicago IL 60611; Eric Hsu-650 Page Mill Road Palo Alto CA 94304-1050 Form 990, Part VI, Section B, Line 11b Form 990 is reviewed by the CEO, and once the CEO approves, it is then forwarded to the board members for their review prior to filing. Board members are encouraged to review and forward their questions, if any, to the CEO. Form 990, Part VI, Section B, Line 12c Officers, directors, and key employees are covered. Any and all conflicts are reviewed by disinterested board members and if needed by legal counsel. Persons with a conflict of interest will be restricted from making any key decisions for MRF as they relate to the interest, unless otherwise approved by the majority of the disinterested parties Form 990, Part VI, Section B, Line 15 Compensation is determined by the Board of Directors Form 990, Part VI, Section C, Line 19 Financial Statements, governing documents, and policies are available upon request. Form 990, Part IX, Line 11g General Consulting